Lifeward (LFWD) investor relations material

Company overview and business model

• Designs, develops, and commercializes medical devices for physical rehabilitation and recovery, including exoskeletons and anti-gravity systems for clinical and home use.

• Product portfolio includes ReWalk exoskeletons for spinal cord injury, ReStore Exo-Suit for stroke rehabilitation, and AlterG Anti-Gravity systems.

• Expanded offerings through internal development, distribution agreements, and acquisitions, notably acquiring AlterG in 2023 and Oratech Pharma in 2026.

• Operates globally, with products in over 6,000 facilities across more than 40 countries.

Financial performance and metrics

• Paid approximately $19 million in cash for the AlterG acquisition in 2023; no additional earnout payments were triggered.

• Issued $10 million in senior secured convertible notes as part of the Oratech Pharma acquisition, with potential for an additional $10 million based on performance milestones.

• Auditors have raised substantial doubt about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling shareholders.

• May receive proceeds from cash exercise of warrants, intended for general corporate purposes.

• Bears all costs related to registration of shares, while selling shareholders cover their own sale-related expenses.